Copyright
©The Author(s) 2020.
World J Pharmacol. Oct 28, 2020; 9(1): 1-12
Published online Oct 28, 2020. doi: 10.5497/wjp.v9.i1.1
Published online Oct 28, 2020. doi: 10.5497/wjp.v9.i1.1
Table 3 Medical treatment of nonalcoholic steatohepatitis
| Insulin sensitization | |
| PPAR receptor agonists | Tropifexor |
| Glucagon like peptide 1 | NGM282 |
| Farnesoid X receptor agonists | |
| Inhibiting lipogenesis | |
| Acetyl coenzyme a carboxylase inhibitors | |
| Aramchol | |
| Modulating lipid metabolism | |
| Polyunsaturated fatty acids | |
| Ezetimibe | |
| Resmetirom | |
| Inhibiting oxidative injury | |
| Vitamin E | |
| Anti-fibrotics | |
| Simtuzumab | |
| Galectin-3 inhibitors | |
| Anti-inflammatory and anti-apoptotic agents | |
| Caspase inhibitors | |
| Chemokine receptor 2 and 5 inhibitors | |
| Manipulating the intestinal microbiome | |
| Antibiotics, probiotics, fecal microbiota transplantation | |
| New and emerging treatments | |
| Apical sodium dependent bile acid transporter inhibitors | |
| Apoptosis signal kinase-1 inhibitors | |
| Protein kinase inhibitors | |
| Toll-like receptor 4 antagonists |
- Citation: Mukherjee S. Advances in the treatment of nonalcoholic steatohepatitis. World J Pharmacol 2020; 9(1): 1-12
- URL: https://www.wjgnet.com/2220-3192/full/v9/i1/1.htm
- DOI: https://dx.doi.org/10.5497/wjp.v9.i1.1